Resumen
La psicosis en enfermedad de Parkinson es una entidad recientemente descrita cuya importancia radica en su alta morbilidad y mal pronóstico asociados. Su diagnóstico y manejo representan un reto clínico cotidiano. Sin embargo, el conocimiento de su definición y criterios diagnósticos, el uso de determinadas escalas de severidad y seguimiento y el ejercicio terapéutico riguroso permitirán al clínico abordar en forma sistemática y exitosa este tipo de paciente.
Citas
Fénelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 2010;289:12-7.
Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease. Drugs Aging. 2008;25:665-82.
Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000;123(Pt 4):733-45.
Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. 1999;56:595-601.
Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001;70:734-8.
Fénelon G, Soulas T, Zenasni F, Cleret de Langavant L. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25:763-6.
Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64:5335-.
Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: A retrospective autopsy study. Lancet Neurol. 2005;4:605-10.
Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W Murphy D, et al. Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH Work Group. Mov Disord. 2007;22:1061-8.
Pascual-Sedano B. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. 2015 Mov Disord. 2016;31(1):45-52.
Beaulieu-Boire I, Lang AE. Behavioral effects of levodopa. Mov Disord 2015;30:90-102.
Stowe RL, Ives NJ, Clarke C, van Hilten J, Ferreira J, Hawker RJ, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008:CD006564.
Baker WL, Silver D, White CM, Kluger J, Aberle J, Patel A, et al. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord. 2009;15:287-94.
Papapetropoulos S, Argyriou A, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol. 2005;252:1223-8.
Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001;70:727-33.
Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm. 2004;111:1447-53.
Biglan KM, Holloway RG, McDermott MP, Richard IH. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007;69:187-95.
Sanchez-Ramos JR, Ortoll R, Paulson GW Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996;53:1265-8.
Weintraub D, Chen P, Ignacio R V, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 2011;68:899-904.
Wang J, Si Y-M, Liu Z-L, Yu L. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease. Pharmacogenetics. 2003;13:365-9.
Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998;21:289-95.
Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 2008;25:665-82.
Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W, et al. Lewy body dementia and Parkinson's disease with dementia. J Neurol 2008;255:39-47.
Friedberg G, Zoldan J, Weizman A, Melamed E. Parkinson psychosis rating scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol. 1998;21:280-4.
Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003;60:1756-61.
Brandstaedter D, Spieker S, Ulm G, Siebert U, Eichhorn TE, Krieg JC, et al. Development and evaluation of the Parkinson Psychosis Questionnaire. A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease. J Neurol. 2005;252:1060-6.
Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Alexander I. Tröster AI, Poewe W, et al. Task force report, scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Dis. 2008;23:484-500.
Henderson MJ, Mellers JDC. Psychosis in Parkinson's disease: between a rock and a hard place'. Int Rev Psychiatry. 2000;12:319-34.
Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord. 2005;20:104-5.
Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:311-3.
Ozer F, Meral H, Aydin B, Hanoglu L, Aydemir T, Oral T. Electroconvulsive therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J ECT. 2005;21:125-7.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.